Skip to content
DataLookout
Menu

STAR-VACCNCT07888647

IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Overall Survival
Timeframe: Date of randomization to death from any cause, an average of 84 months.

Secondary (2)

Progression-free survival
Patient reported outcome

Arms and interventions

VaccinationExperimental

Patient in the Vaccination-Arm receives IDH1 peptide vaccine (IDH1-vac) with topical imiquimod (Aldara) and Temzolomid as background treatment.

Sham-VaccinationSham comparator

Patient in the Sham-Vaccination-Arm receives Immune stimulator (IS-vac) with topical imiquimod (Aldara) and Temzolomid as background treatment

Biologicals: IDH1-vac, IS-vac

Drugs: Temozolomide (TMZ), Imiquimod 5 % Cream

Sites

13 sites in 1 country